News

November 15, 2019

Treatment With VBI-1901 Linked to Tumor Stabilization in Recurrent Gliobastoma Patients in Phase 1/2 Trial

News

Immune responses triggered by the investigational cancer vaccine VBI-1901 correlate with the stabilization of tumor size in patients with recurrent glioblastoma (GBM), a common and aggressive brain cancer, according ... Read more

November 13, 2019

CytomX Initiates Phase 2 Trial Testing CX-072, Yervoy Combo in Relapsed or Refractory Melanoma

News

CytomX Therapeutics has initiated a Phase 2 clinical trial to test a combination of its probody CX-072 — a type of engineered antibody — with Yervoy (ipilimumab) for treating ... Read more

November 11, 2019

2 Imfinzi Combos Delay Cancer Progression in Metastatic NSCLC, Interim Phase 3 Data Show

News

Adding Imfinzi (durvalumab) — alone or in combination with tremelimumab — to standard first-line chemotherapy significantly delayed disease progression or death in people with metastatic non-small cell lung cancer (NSCLC), compared ... Read more

November 8, 2019

MDNA55 Increases Survival in Glioblastoma, Notably in Patients With High ILR4 Levels, Early Trial Data Show

News

The investigational therapy MDNA55 increases survival in people with recurrent glioblastoma, a type of brain cancer — especially in those who produce high levels of ILR4, a marker of ... Read more

November 6, 2019

Opdivo-Yervoy Plus Shorter Chemotherapy Course Extends Survival of Patients with Advanced Lung Cancer, Early Trial Data Show

News

First-line treatment with a combination of Opdivo (nivolumab) and low-dose Yervoy (ipilimumab) added to a shorter course of chemotherapy significantly extends the survival of people with advanced non-small cell ... Read more

November 4, 2019

Tecentriq-Avastin Prolongs Life of Patients with Advanced Liver Cancer in Trial, Roche Reports

News

A combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) extends overall survival and the time lived without disease progression in people with newly-diagnosed, inoperable hepatocellular carcinoma (HCC), the most common ... Read more

October 30, 2019October 30, 2019

European Commission Approves Bavencio-Inlyta for First-line Treatment of Advanced Kidney Cancer

News

The European Commission (EC) has approved a combination regimen of Bavencio (avelumab) injections plus Inlyta (axitinib) tablets for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC), ... Read more

October 28, 2019October 28, 2019

Keytruda Survival Benefits Similar to Chemo for Relapsed Mesothelioma, Phase 3 Trial Finds

News

Treatment with the immunotherapy Keytruda (pembrolizumab) appears to be as effective as conventional chemotherapy for treating malignant pleural mesothelioma patients who relapse after one course of platinum-based chemotherapy, data ... Read more

October 25, 2019

Blincyto Increases Survival of ALL Children, Adolescents After First Relapse, Phase 3 Trials Show

News

Blincyto (blinatumomab) increases overall survival and disease-free survival in children and adolescents with B-cell acute lymphoblastic leukemia (ALL) who already had their first relapse, data from Phase 3 trials ... Read more

October 23, 2019November 7, 2019

CHMP Favors Keytruda Regimens to Treat Recurrent Head and Neck Cancers

News

The Committee for Medicinal Products for Human Use (CHMP), a branch of the European Medicines Agency (EMA), has recommended that two regimens of Keytruda (pembrolizumab) be approved in Europe for ... Read more

Pin It on Pinterest